Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Liabilities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Total Liabilities for 11 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 12.11% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Sep 2025, down 12.11%, and an annual FY2024 reading of $10.7 million, up 41.07% over the prior year.
  • Total Liabilities was $7.5 million for Q3 2025 at Kiora Pharmaceuticals, down from $9.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $10.7 million in Q4 2024 and bottomed at -$23.7 million in Q1 2025.
  • Average Total Liabilities over 5 years is $4.8 million, with a median of $6.9 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 1449.66% in 2022, then crashed 414.51% in 2025.
  • Year by year, Total Liabilities stood at $5.6 million in 2021, then rose by 28.64% to $7.1 million in 2022, then rose by 6.46% to $7.6 million in 2023, then soared by 41.07% to $10.7 million in 2024, then crashed by 30.51% to $7.5 million in 2025.
  • Business Quant data shows Total Liabilities for KPRX at $7.5 million in Q3 2025, $9.8 million in Q2 2025, and -$23.7 million in Q1 2025.